11th Aug 2021 15:24
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 10 August 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 3,293,365 4.95 | 134,113 0.20 | ||||
(2) Derivatives (other than options) | 124,443 0.19 |
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 3,417,808 5.14 | 134,113 0.20 | ||||
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Purchases Purchases
Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales | 1 1
100 4,200 6,296 300 1,201 672 8,000 1,700 8,900 26,848 5,100 600 34,671 9,843 13,358 13,783 1,000 400 29,572 8,107 1,200 700 11,700 4,362 21,985 8,650 11,600 4,600 5,939 1,700 2,400 416 3,060 295 3,100 700 1,900 100 100 800 300 200 500 | 2.3100 USD 2.3150 USD
2.3000 USD 2.3035 USD 2.3050 USD 2.3067 USD 2.3100 USD 2.3115 USD 2.3146 USD 2.3147 USD 2.3150 USD 2.3161 USD 2.3180 USD 2.3183 USD 2.3187 USD 2.3188 USD 2.3198 USD 2.3200 USD 2.3210 USD 2.3225 USD 2.3241 USD 2.3242 USD 2.3250 USD 2.3257 USD 2.3262 USD 2.3264 USD 2.3272 USD 2.3277 USD 2.3296 USD 2.3300 USD 2.3339 USD 2.3350 USD 2.3367 USD 2.3384 USD 2.3392 USD 2.3398 USD 2.3400 USD 2.3450 USD 2.3500 USD 2.3550 USD 2.3700 USD 2.3800 USD 2.3833 USD 2.4050 USD 2.4150 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 11 August 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
Related Shares:
Xeris Biopharma